Latest Ratios: P/E Ratio 6.2x · EV/EBITDA N/A · ROE 70.0%. (1996–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $360M | $349M | $229M | $107M | $24M | $33M | $145M | $165M | $339M | $660M | $166M |
| Enterprise Value | $306M | $295M | $228M | $98M | $18M | $10M | $142M | $43M | $351M | $522M | $97M |
| P/E Ratio → | 6.25 | 5.22 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 61.79 | 59.89 | — | 30.60 | 17.13 | 11.16 | 14.55 | — | 113.18 | 788.24 | 186.44 |
| P/B Ratio | 2.62 | 2.19 | 5.19 | 7.22 | 0.90 | 0.79 | 1.42 | 0.92 | 2.53 | 3.88 | 1.67 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 50.70 | — | 28.01 | 12.46 | 3.30 | 14.16 | — | 116.94 | 623.66 | 108.67 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 73.7% | 73.7% | — | 54.1% | 68.2% | 100.0% | 100.0% | — | -1190.8% | -1929.7% | -1098.5% |
| Operating Margin | -1536.9% | -1536.9% | — | -1346.7% | -3600.8% | -2994.5% | -814.2% | — | -1940.2% | -3325.7% | -2686.3% |
| Net Profit Margin | 1223.1% | 1223.1% | — | -1548.2% | -2807.4% | -2831.2% | -842.3% | — | -1890.3% | -3263.9% | -2460.4% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 70.0% | 70.0% | -216.6% | -260.6% | -114.8% | -117.2% | -60.0% | -48.8% | -37.3% | -20.3% | -26.2% |
| ROA | 43.3% | 43.3% | -73.7% | -84.5% | -55.2% | -73.6% | -45.0% | -38.4% | -32.1% | -18.9% | -22.9% |
| ROIC | -89.8% | -89.8% | -194.7% | -272.7% | -195.9% | -114.7% | -78.4% | -57.1% | -49.1% | -67.0% | -58.2% |
| ROCE | -63.4% | -63.4% | -89.9% | -88.1% | -85.3% | -104.3% | -55.4% | -45.5% | -35.6% | -20.2% | -26.3% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.16 | 0.16 | 0.52 | 0.36 | 0.29 | 0.22 | 0.09 | 0.04 | 0.22 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.34 | -0.01 | -0.61 | -0.25 | -0.56 | -0.04 | -0.68 | 0.08 | -0.81 | -0.70 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -23.92 | -23.92 | -14.15 | -128.64 | -52.93 | -22.23 | -19.47 | -192.72 | -5151.91 | -3414.88 | -3645.50 |
Net cash position: cash ($78M) exceeds total debt ($25M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.93 | 6.93 | 6.08 | 4.15 | 6.83 | 3.39 | 2.33 | 3.42 | 4.37 | 25.07 | 8.37 |
| Quick Ratio | 6.74 | 6.74 | 6.08 | 4.15 | 6.83 | 3.39 | 2.33 | 3.42 | 4.37 | 25.07 | 8.37 |
| Cash Ratio | 6.47 | 6.47 | 5.89 | 3.89 | 6.70 | 2.71 | 2.26 | 3.34 | 4.17 | 24.57 | 8.33 |
| Asset Turnover | — | 0.03 | — | 0.05 | 0.02 | 0.04 | 0.07 | — | 0.02 | 0.00 | 0.01 |
| Inventory Turnover | 0.28 | 0.28 | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 421.13 | — | 254.87 | 48.53 | 365.00 | — | — | 9.86 | 46.66 | 50.91 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 16.0% | 19.2% | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $66M | $41M | $21M | $8M | $4M | $4M | $2M | $2M | $2M | $1M |
Regulatory-driven liquidity depletion
As reported in financial statements, Abeona's P/S ratio of 54.94 appears significantly elevated compared to broader biotech benchmarks, reflecting a market valuation that is heavily contingent on speculative future commercial success rather than any current, recurring revenue streams or established earnings power within the gene therapy sector.
The current P/S multiple is largely an artifact of the company's pre-commercial status and the lack of a stable revenue base. Investors should monitor this metric with caution, as it implies high growth expectations that remain entirely dependent on the successful regulatory approval and subsequent commercial launch of EB-101.
Based on the provided quarterly data, Abeona's ROIC has consistently remained in negative territory, reaching -16.3% in 2026Q1, which underscores the significant capital destruction inherent in maintaining a specialized manufacturing facility without a corresponding commercial product to generate sustainable returns on invested capital for shareholders.
The persistent negative ROIC reflects the high fixed-cost burden of the Cleveland manufacturing site relative to the company's current clinical-stage output. This trend suggests that until the firm achieves commercial scale, capital efficiency will likely remain strained, necessitating further external funding to sustain operations.
According to recent financial disclosures, the company's cash conversion cycle has exhibited extreme volatility, swinging from -2808 days in 2025Q2 to 64 days in 2026Q1, which highlights the operational challenges of managing inventory and payables in a pre-revenue environment characterized by lumpy, non-recurring milestone-based income.
The erratic nature of these efficiency metrics is typical for a firm transitioning between clinical development and commercial readiness. Investors should interpret these figures as evidence of operational instability rather than a reflection of long-term working capital management capabilities.
As reported in financial statements, the company's current ratio of 5.89 in 2026Q1 provides a superficial appearance of liquidity, yet this buffer is rapidly depleting as the firm navigates the extended development timelines and additional validation requirements mandated by the FDA's recent Complete Response Letter.
While the current ratio remains above parity, the underlying cash burn rate suggests that the liquidity position is more vulnerable than the headline numbers imply. The company's reliance on capital markets for future funding remains a critical risk factor that could lead to significant shareholder dilution.
The P/E ratio of 5.55 is the most commonly misapplied metric for Abeona, as it erroneously suggests profitability where none exists, failing to account for the non-recurring accounting gains that have temporarily inflated net income and masked the company's underlying, persistent operational cash burn.
Analysts should instead focus on the cash burn rate and the remaining cash runway, as these metrics provide a more accurate assessment of the company's viability. Using P/E to value a pre-commercial biotech firm is fundamentally flawed and risks misrepresenting the firm's true financial health.
Includes 30+ ratios · 30 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ABEO stock.
Abeona Therapeutics Inc.'s current P/E ratio is 6.2x. The historical average is 4.7x. This places it at the 100th percentile of its historical range.
Abeona Therapeutics Inc.'s return on equity (ROE) is 70.0%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -120.7%.
Based on historical data, Abeona Therapeutics Inc. is trading at a P/E of 6.2x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Abeona Therapeutics Inc. has 73.7% gross margin and -1536.9% operating margin.